Sæmundur Rögnvaldsson, MD, PhD, University of Iceland, Reykjavik, Iceland, explores the evolving landscape of screening and prognostication for patients with monoclonal gammopathy of undetermined significance (MGUS). He mentions the potential benefits of MGUS screening that are being investigated in the iStopMM trial (NCT03327597), the optimization of patient monitoring methods, and the importance of enhancing our understanding of MGUS progression to multiple myeloma (MM). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
